Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients who have received prior treatment with a Lenalidomide based regimen

Trial Profile

A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients who have received prior treatment with a Lenalidomide based regimen

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2018

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms DARIA
  • Most Recent Events

    • 05 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top